StockData
Treace Medical Concepts, Inc. logo

Treace Medical Concepts, Inc. (TMCI) stock

TMCINasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/3031% below fair value
$4.44+0.02 (+0.45%)

Close on Nov 17, 2026Market cap $288.75MP/E –Yield –

Treace Medical Concepts r&d expenses

Research and development expenses are spending on new products and technology.

Treace Medical Concepts's R&D Expenses for the twelve months ending Jun 30, 2026 was $18.22M, down 14.2% year over year. For fiscal 2025 it was $20.28M, down 1.5% from the year before. The highest annual figure on record is $20.59M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$20.28M-1.5%
FY2024Dec 31, 2024$20.59M+33.3%
FY2023Dec 31, 2023$15.44M+13.7%
FY2022Dec 31, 2022$13.58M+33.1%
FY2021Dec 31, 2021$10.20M+74.5%
FY2020Dec 31, 2020$5.85M+15.3%
FY2019Dec 31, 2019$5.07M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$4.38M-20.4%
Q1 FY2026Mar 31, 2026$4.62M-16.9%
Q4 FY2025Dec 31, 2025$4.54M-12.8%
Q3 FY2025Sep 30, 2025$4.68M-5.7%
Q2 FY2025Jun 30, 2025$5.50M+6.6%
Q1 FY2025Mar 31, 2025$5.56M+5.8%
Q4 FY2024Dec 31, 2024$5.21M+25.5%
Q3 FY2024Sep 30, 2024$4.96M+14.1%
Q2 FY2024Jun 30, 2024$5.16M+46.3%
Q1 FY2024Mar 31, 2024$5.26M+54.1%
Q4 FY2023Dec 31, 2023$4.15M+10.7%
Q3 FY2023Sep 30, 2023$4.35M+14.5%
Q2 FY2023Jun 30, 2023$3.53M+18.2%
Q1 FY2023Mar 31, 2023$3.41M+11.8%
Q4 FY2022Dec 31, 2022$3.75M+11.0%
Q3 FY2022Sep 30, 2022$3.80M+49.7%
Q2 FY2022Jun 30, 2022$2.98M+23.2%
Q1 FY2022Mar 31, 2022$3.05M+63.4%
Q4 FY2021Dec 31, 2021$3.38M+75.7%
Q3 FY2021Sep 30, 2021$2.54M+67.9%
Q2 FY2021Jun 30, 2021$2.42M+146.6%
Q1 FY2021Mar 31, 2021$1.87M+30.4%
Q4 FY2020Dec 31, 2020$1.92M–
Q3 FY2020Sep 30, 2020$1.51M–
Q2 FY2020Jun 30, 2020$982.00K–
Q1 FY2020Mar 31, 2020$1.43M–

More Treace Medical Concepts figures

See a number that looks wrong?